Meeting
2024 ASCO Gastrointestinal Cancers Symposium
The implication of failure patterns after neoadjuvant chemoradiotherapy with small involved-field in esophageal squamous cell carcinoma.
Authors
Hyunju Shin
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Hyunju Shin , Dongryul Oh , Jae Myoung Noh , Kyungmi Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 376)
DOI
10.1200/JCO.2024.42.3_suppl.376
Abstract #
376
Poster Bd #
H18
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
M1a disease should be reconsidered in esophageal cancer staging system from the perspective of treatment response and survival after definitive concurrent chemoradiotherapy.
First Author: Tae Ryong Chung
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Recurrence-free survival as a surrogate for overall survival in esophageal squamous cell carcinoma: Nationwide real-world data from Japan.
First Author: Jun Okui
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).
First Author: Changying Guo
Poster
2023 ASCO Breakthrough
Impact of pathological response and recurrence pattern on the survival of patients who develop recurrence from neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).
First Author: Chien Huai Chuang